Development of Database and Genomic Medicine for von Hippel-Lindau Disease in Japan

von Hippel-Lindau (VHL) disease is a hereditary tumor disease in which tumors develop in multiple organs, not only as hemangioblastomas (HBs) in the central nervous system, but also as kidney tumors, pheochromocytomas, and so on. Much about the epidemiology of VHL disease remained unknown until fair...

Full description

Saved in:
Bibliographic Details
Published in:Neurologia medico-chirurgica 2017, Vol.57(2), pp.59-65
Main Authors: TAKAYANAGI, Shunsaku, MUKASA, Akitake, NAKATOMI, Hirofumi, KANNO, Hiroshi, KURATSU, Jun-ichi, NISHIKAWA, Ryo, MISHIMA, Kazuhiko, NATSUME, Atushi, WAKABAYASHI, Toshihiko, HOUKIN, Kiyohiro, TERASAKA, Shunsuke, YAO, Masahiro, SHINOHARA, Nobuo, SHUIN, Taro, SAITO, Nobuhito
Format: Article
Language:English
Subjects:
Central nervous system
Diagnosis
Epidemiology
Genetic counseling
Genetic screening
genomic medicine
Patients
Review
Tumors
VHL disease
VHL protein
Von Hippel-Lindau disease
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:von Hippel-Lindau (VHL) disease is a hereditary tumor disease in which tumors develop in multiple organs, not only as hemangioblastomas (HBs) in the central nervous system, but also as kidney tumors, pheochromocytomas, and so on. Much about the epidemiology of VHL disease remained unknown until fairly recently in Japan, leading to calls for the establishment of a VHL disease epidemiological database in Japanese. To elucidate its epidemiology in Japan, the Japanese Ministry of Health, Labour and Welfare created the VHL Disease Study Group, which was put in charge of carrying out a nationwide epidemiological survey. The survey found close to 400 Japanese VHL disease patients throughout the country. Based on those results, the VHL Disease Study Group created the VHL Disease Treatment Guideline and also a severity classification. It is thought that the prognosis of VHL disease patients can be improved by performing genetic diagnosis and careful follow-up. Accordingly, the University of Tokyo Hospital put in place an in-hospital system for implementing genomic medicine for VHL disease based on genetic diagnosis. For that system, it was especially important to establish (I) accurate genetic diagnostic techniques, (II) genetic counseling capabilities for the patients and their families, and (III) a system of cooperation among multiple departments, including urology departments, and so on. Further elucidation of the epidemiology and the development of genomic medicine are needed to improve the treatment results of VHL disease in Japan.
ISSN:0470-8105
1349-8029
DOI:10.2176/nmc.ra.2016-0206